Aligos Therapeutics, Inc. (ALGS)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
6.91 USD
-0.16
(-2.263%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.02 +0.11 (1.592%) ⇧ (Aug. 28, 2026, 6:37 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:51 a.m. EDT
The investment case here is fundamentally broken. The business has suffered a catastrophic multi-year decline, dropping nearly 98% over the last four years with every single year showing negative growth. This is not a temporary setback; the market has consistently reassessed the company downward for years, evidenced by the relentless price erosion. While the company reports revenue growth of roughly 28%, this is mathematically impossible to sustain while burning through massive cash reserves (negative free cash flow of over $61 million) and posting gross margins of -180%. The balance sheet is fragile, with debt significantly exceeding equity, and the company is hemorrhaging cash without a clear path to profitability. Analyst targets suggest a potential recovery to $45-$56, but these are speculative hopes rather than grounded valuations given the deteriorating operational reality. For the short term, the stock is volatile and trading below its 50-day average, offering no clear momentum edge. There is no dividend to provide income. This is a high-risk speculative vehicle where the odds of permanent capital loss remain high due to the severe structural decline. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.142094 |
| AutoARIMA | 0.143489 |
| AutoETS | 0.143492 |
| AutoTheta | 0.179269 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 3.56 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.376 |
| Excess Kurtosis | -0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.99 |
| Revenue per Share | 3.03 |
| Market Cap | 43,149,896 |
| Forward P/E | -1.37 |
| Beta | 2.28 |
| Profit Margins | -241.01% |
| Website | https://www.aligos.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.33427495 |
| Address1 | One Corporate Drive |
| Address2 | 2nd Floor |
| All Time High | 937.75 |
| All Time Low | 3.76 |
| Ask | 7.4 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 69,550 |
| Average Daily Volume3 Month | 175,909 |
| Average Volume | 175,909 |
| Average Volume10Days | 69,550 |
| Beta | 2.284 |
| Bid | 4.97 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 5.112 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.91 |
| Current Ratio | 2.192 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 7.1 |
| Day Low | 6.6401 |
| Debt To Equity | 10.99 |
| Display Name | Aligos Therapeutics |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -77,916,000 |
| Ebitda Margins | -2.47211 |
| Enterprise To Ebitda | -0.209 |
| Enterprise To Revenue | 0.516 |
| Enterprise Value | 16,272,896 |
| Eps Current Year | -6.578 |
| Eps Forward | -5.054 |
| Eps Trailing Twelve Months | -7.52 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.8301 |
| Fifty Day Average Change | 1.0798998 |
| Fifty Day Average Change Percent | 0.18522835 |
| Fifty Two Week Change Percent | -33.427494 |
| Fifty Two Week High | 13.689 |
| Fifty Two Week High Change | -6.7790003 |
| Fifty Two Week High Change Percent | -0.49521515 |
| Fifty Two Week Low | 3.98 |
| Fifty Two Week Low Change | 2.9299998 |
| Fifty Two Week Low Change Percent | 0.73618084 |
| Fifty Two Week Range | 3.98 - 13.689 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,602,855,000,000 |
| Float Shares | 3,702,711 |
| Forward Eps | -5.054 |
| Forward P E | -1.3672339 |
| Free Cashflow | -61,390,248 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 82 |
| Fullday Change | -0.16 |
| Fullday Change Percent | -2.26309 |
| Fullday Price | 7.02 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -1.8040199 |
| Gross Profits | -56,859,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.106429994 |
| Held Percent Institutions | 0.45645002 |
| Implied Shares Outstanding | 6,244,558 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,025,600 |
| Last Split Factor | 1:25 |
| Long Business Summary | Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. |
| Long Name | Aligos Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 43,149,896 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_581475891 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -75,962,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 44,211,470 |
| Number Of Analyst Opinions | 7 |
| Open | 7.025 |
| Operating Cashflow | -94,168,000 |
| Operating Margins | -0.06804 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 800 466 6059 |
| Post Market Change | 0.11000013 |
| Post Market Change Percent | 1.5918977 |
| Post Market Price | 7.02 |
| Post Market Time | 1,787,956,657 |
| Previous Close | 7.07 |
| Price Eps Current Year | -1.0504712 |
| Price Hint | 2 |
| Price To Book | 1.3517214 |
| Price To Sales Trailing12 Months | 1.3690556 |
| Profit Margins | -2.41011 |
| Quick Ratio | 2.052 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.16 |
| Regular Market Change Percent | -2.26309 |
| Regular Market Day High | 7.1 |
| Regular Market Day Low | 6.6401 |
| Regular Market Day Range | 6.6401 - 7.1 |
| Regular Market Open | 7.025 |
| Regular Market Previous Close | 7.07 |
| Regular Market Price | 6.91 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 39,065 |
| Return On Assets | -0.49118 |
| Return On Equity | -1.13588 |
| Revenue Growth | 27.785 |
| Revenue Per Share | 3.03 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 5,444,558 |
| Shares Percent Shares Out | 0.091000006 |
| Shares Short | 568,056 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 521,416 |
| Short Name | Aligos Therapeutics, Inc. |
| Short Percent Of Float | 0.1071 |
| Short Ratio | 3.95 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALGS |
| Target High Price | 175.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 56.28571 |
| Target Median Price | 45.0 |
| Total Cash | 30,381,000 |
| Total Cash Per Share | 4.865 |
| Total Debt | 3,504,000 |
| Total Revenue | 31,518,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.52 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.153625 |
| Two Hundred Day Average Change | -0.24362516 |
| Two Hundred Day Average Change Percent | -0.034056183 |
| Type Disp | Equity |
| Volume | 39,065 |
| Website | https://www.aligos.com |
| Zip | 94,080 |